Ruxolitinib cream for Vitiligo

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
VitiligoRuxolitinib cream - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how well ruxolitinib cream works to treat vitiligo by measuring changes in biomarkers.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 56 weeks

56 weeks
Number of treatment emergency Adverse Events
Week 24
Correlation of CXCL10 biomarker to Vitiligo Area Scoring Index (VASI) Repigmentation response in target lesions
To evaluate change in Immune Biomarkers

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Vehicle Cream BID
1%Tibia fracture
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT04052425) in the Vehicle Cream BID ARM group. Side effects include: Tibia fracture with 1%.

Trial Design

2 Treatment Groups

Ruxolitinib cream
1 of 2
Vehicle Cream
1 of 2

Experimental Treatment

Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: Ruxolitinib cream · Has Placebo Group · Phase 2

Ruxolitinib cream
Drug
Experimental Group · 1 Intervention: Ruxolitinib cream · Intervention Types: Drug
Vehicle Cream
Drug
PlaceboComparator Group · 1 Intervention: Vehicle Cream · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 56 weeks

Who is running the clinical trial?

Incyte CorporationLead Sponsor
315 Previous Clinical Trials
46,515 Total Patients Enrolled
6 Trials studying Vitiligo
1,515 Patients Enrolled for Vitiligo

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
At least one lesion on the skin that is indicative of vitiligo is required in order to conduct a skin biopsy
The person has nonsegmental vitiligo, meaning that they have areas of skin that have lost their pigment
We ask that you discontinue all treatments used to treat vitiligo, including screening and final safety follow-up visits

Who else is applying?

What state do they live in?
New York20.0%
Virginia20.0%
Ontario10.0%
Other50.0%
How old are they?
18 - 6577.8%
65+22.2%
What site did they apply to?
First Oc Dermatology25.0%
UC Irvine25.0%
George Washington Medical Faculty Associates25.0%
Other25.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria30.0%
Met criteria70.0%
Why did patients apply to this trial?
  • "I am an international medical graduate (IMG) recently migrated to USA from Ethiopia due to current political instability. its been my deepest passion participating on study specially my passion diverted toward dermatology and specifically toward vitiligo. i started to see small with patch on my skin while i was on my second year of med school and which symmetrically started to spread on my body and which honestly created unexplainable mental depression to me as young medical student. people started bulling at me and was very traumatizing moment. after coming to USA currently i joined postgraduation program on clinical research at Harvard medical school, which i believe will help me to boost my passion on research and will give good basic background. at mean time when i see this research trial, i didn't even take time to think more about it. i just started submitting the application form to see whether i am eligible for the program or not. i am willing to be part of this trial as a vitiligo victim as a patient. if i am not eligible for this, please kindly request to be part of it, which i don't really know how but use me in any area of study, let me know if i can fit in any area as a young, energetic and enthusiastic medical doctor. i believe todays research trial will defiantly be tomorrows hope for others who also suffer from vitiligo. thank you."
How many prior treatments have patients received?
1100.0%

How responsive is this trial?

Most responsive sites:
  1. Mount Sinai Hospital: < 48 hours
Average response time
  • < 2 Days
Typically responds via
Phone Call100.0%